N–glycan Biopharmaceutical Reference Library - - Chromatography Online
N–glycan Biopharmaceutical Reference Library


The Column
Volume 12, Issue 10, pp. 7

Thirty percent of approved drugs will be based on recombinant monoclonal antibody (rMab) drugs over the next 10 years.1 Glycosylation, the convalent addition of carbohydrates to proteins, can influence properties of rMab drugs and has to be closely monitored during drug development and production. Scientists from the University of California (California, USA) have developed a new liquid chromatography–mass spectrometry (LC–MS) N-glycan library based on eight commercially available recombinant monoclonal antibodies, for the rapid identification of glycosylated structures.1

Carlito Lebrilla, corresponding author of the study, told The Column: “Many of today’s antibody drugs were developed over a decade ago when our methods for the analysis of the glycan were not as advanced. For this reason, there is very little relative effort spent on characterizing glycosylation.” This is now changing, according to Lebrilla, with the emergence of biosimilars and other biologics.

Eight commercial rMab drugs were treated to release N-glycans that were then separated on a porous graphitized column on a chip, and then analyzed using electrospray ionization hybrid quadrupole time-of-flight mass spectrometry (ESI–Q–TOF–MS). The retention time and accurate mass for over 70 structures was recorded within the library, allowing identification of glycosylated structures by matching LC retention times and accurate masses. — B.D.

Reference
1. T. Song, S. Ozcan, A. Becker, and C.B. Lebrilla, Analytical Chemistry DOI: 10.1021/ac501102t (2014).

This story originally appeared in The Column. Click here to view that issue.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters
Global E-newsletters subscribe here:




 

LCGC COLUMNISTS 2014

Column Watch: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments. LATEST: Avoiding Reversed-Phase Chromatography Problems Through Informed Method Development Practices: Choosing the Stationary-Phase Chemistry


Perspectives in Modern HPLC: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: Seven Common Faux Pas in Modern HPLC


MS — The Practical Art: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis


LC Troubleshooting: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: Estimating Resolution for Marginally Separated Peaks


More LCGC Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>


Source: The Column,
Click here